Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Exelixis Inc. (EXEL)

19.82   -0.62 (-3.03%) 01-17 16:00
Open: 20.57 Pre. Close: 20.44
High: 20.57 Low: 19.78
Volume: 2,225,734 Market Cap: 6022M
Exelixis Inc is a part of the healthcare sector. As a biotechnology company, it develops small molecule therapies for the treatment of cancer.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 20.586 - 20.691 20.691 - 20.757
Low: 19.535 - 19.671 19.671 - 19.758
Close: 19.626 - 19.83 19.83 - 19.961

Technical analysis

as of: 2020-01-17 4:35:58 PM
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 24.25     One year: 28.32
Support: Support1: 18.25    Support2: 16.70
Resistance: Resistance1: 20.76    Resistance2: 24.25
Pivot: 18.60
Moving Average: MA(5): 19.76     MA(20): 18.62
MA(100): 17.70     MA(250): 20.01
MACD: MACD(12,26): 0.63     Signal(9): 0.45
Stochastic oscillator: %K(14,3): 86.77     %D(3): 89.13
RSI: RSI(14): 62.32
52-week: High: 25.31  Low: 15.02  Change(%): -10.4
Average Vol(K): 3-Month: 317609  10-Days: 420557

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.
EXEL has closed below upper band by 20.5%. Bollinger Bands are 75.2% wider than normal. The large width of the bands suggest high volatility as compared to EXEL's normal range. The bands have been in this wide range for 2 bars. This is a sign that the current trend might continue.

Headline News

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Exelixis Outlines Key Priorities and Anticipated Milestones for 2020-21, Announces Preliminary Fourth Quarter and Full Year 2019 Financial Results, and Provides 2020 Financial Guidance
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced its key priorities and anticipated milestones for 2020-21, including generating top-line data from key clinical trials, completing enrollment of ongoing studies, initiating new pivotal trials, and progressing its mid-stage and early pipeline. The company intends to make appropriate investments to maximize the clinical development opportunities for CABOMETYX® (cabozantinib), which Exelixis believes could lead to as m

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  Nasdaq Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 303.85
Shares Float (M) 294.02
% Held by Insiders 3.20
% Held by Institutions 79.60
Shares Short (K) 15890
Shares Short P. Month (K)

Stock Financials

EPS 1.960
Book Value (p.s.) 5.280
PEG Ratio 0.41
Profit Margin 64.05
Operating Margin 42.30
Return on Assets (ttm) 18.0
Return on Equity (ttm) 48.6
Qtrly Rev. Growth 20.5
Gross Profit (p.s.) 2.727
Sales Per Share
EBITDA (p.s.) 1.358
Qtrly Earnings Growth -23.00
Operating Cash Flow (M) 473.53
Levered Free Cash Flow (M) 303.56

Stock Valuations

P/E 10.11
P/E Growth Ratio -0.03
P/BV 3.75
P/S 6.25
P/CF 12.72

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.